cvot tirzepatide π‘ New insight in diabetes care: In patients with T2DM and ASCVD, the SURPASS-CVOT trial found that was noninferior to dulaglutide for major cardiovascular events (12.2% vs 13.1%; HR 0.92). What SURPASS-CVOT: Tirzepatide Significantly Reduces Major
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Aug 9 - Aug 14


01774-X/asset/3608bfb3-6329-4132-95b7-cc3434437493/main.assets/gr2_lrg.jpg)



























